.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Cipla
Fish and Richardson
Harvard Business School
UBS
McKinsey
Cantor Fitzgerald
Chinese Patent Office
Queensland Health

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050007

« Back to Dashboard
NDA 050007 describes VIBRAMYCIN, which is a drug marketed by Pfizer and is included in four NDAs. It is available from two suppliers. Additional details are available on the VIBRAMYCIN profile page.

The generic ingredient in VIBRAMYCIN is doxycycline calcium. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the doxycycline calcium profile page.

Summary for NDA: 050007

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antibacterials
Dental and Oral Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 050007

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIBRAMYCIN
doxycycline hyclate
CAPSULE;ORAL 050007 NDA Pfizer Laboratories Div Pfizer Inc 0069-0950 0069-0950-50 50 CAPSULE in 1 BOTTLE (0069-0950-50)
VIBRAMYCIN
doxycycline hyclate
CAPSULE;ORAL 050007 NDA AUTHORIZED GENERIC Greenstone LLC 59762-3690 59762-3690-1 50 CAPSULE in 1 BOTTLE (59762-3690-1)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 100MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Fish and Richardson
Johnson and Johnson
Mallinckrodt
Cerilliant
Express Scripts
Fuji
Boehringer Ingelheim
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot